Kinase Chemistry – Just a year and a half behind the times.

Archive for July 26th, 2007

clinical roundup

Posted by kinasepro on July 26, 2007

Supergen initiates dosing of flt3 inhibitor MP-470: ph1 ‘advanced-stage solid tumors.’

Entremed initiates trial for Aurora inihbitor MKC-1: Ph1 Leukemia

Kinex gets the FDA go-ahead for Src inhibitor KX2-391: lymphoma or solid tumors (though despite the press release, it’s not the first non-atp competitive kinase inhibitor to enter the clinic. The MEK inhibitors were)

Posted in clinical | Leave a Comment »

The Thursday List

Posted by kinasepro on July 26, 2007

WO/2007/082470 Shanghai Henriu
WO/2007/082956 pi3k Serono
WO/2007/083017 IGFl-R Aventis
WO/2007/083096 aurora AstraZeneca
WO/2007/083978 GSK3, Aurora Crystal Genomics
WO/2007/084391 PKB Amgen
WO/2007/084557 Jak Vertex
WO/2007/084560 bRaf Signal
WO/2007/084667 Rho OSI
WO/2007/084786 pi3k Novartis (Chiron)
WO/2007/084815 EGF JnJ
WO/2007/084857 Resveratrol Harvard
WO/2007/084875 EGF&Vegf

US20070173649 p38 Vertex
US20070173537 vegf Mitsubishi
US20070173530 Aerie
US20070173525 IGFR? Merck
US20070173519 MK2 Teijin
US20070173516 Aurora Vertex
US20070173506 PKB Amgen
US20070173503 CDK2 Sanofi-Aventis
US20070173500 Allergan
US20070173488 cMet etc. SGX

Posted in Application List | Leave a Comment »